How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

4,957 results for

Severe Persistent Asthma

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

81. A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma

Sponsor: GlaxoSmithKline Information provided by (Responsible Party): GlaxoSmithKline Study Details Study Description Go to Brief Summary: Mepolizumab, a humanized monoclonal antibody, has been developed as an add-on treatment for subjects with severe asthma with eosinophilic inflammation. Current asthma treatment guidelines offer minimal options for the severe asthmatic subjects on intensive therapy with frequent exacerbations. There is a significant unmet medical need to provide better treatment (...) options for this segment of the asthma population. Thus, this study is designed to evaluate the efficacy and safety of mepolizumab in Chinese severe asthmatic subjects with eosinophilic inflammation. A total number of 300 subjects will be randomized in 1:1 ratio to receive either mepolizumab or placebo along with existing standard of care therapy. The maximum study duration will be 56 weeks. Condition or disease Intervention/treatment Phase Asthma Drug: Mepolizumab 100 milligrams Drug: Placebo Drug

2018 Clinical Trials

82. Identifying Serum Cytokine Profiles of Distinct Inflammatory Phenotypes in Severe Asthma

University Information provided by (Responsible Party): Murat Türk, TC Erciyes University Study Details Study Description Go to Brief Summary: The aim of this study is to determine and compare serum cytokine levels of six different severe asthma inflammatory phenotypes differentiated by their atopy, peripheral eosinophilia and/or chronic rhinosinusitis and/or nasal polyposis status. Condition or disease Asthma Persistent Asthma, Allergic Eosinophilic Asthma Chronic Rhinosinusitis (Diagnosis) Detailed (...) will be selected from the Erciyes University Allergy Clinic admisisons. Control group wil be selected from the Erciyes University Allergy Clinic admisisons and from the volunteers. Criteria Inclusion Criteria (for disease groups): Patients diagnosed with severe asthma and followed-up at least 6 months at our clinic Asthma that can only be complete or partly controlled with Global Initiative for Asthma (GINA) 4-5 treatment Asthmatics that are eligible for the defined phenotypes At least one perennial allergen

2018 Clinical Trials

83. Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics

Sponsor: University of North Carolina, Chapel Hill Collaborator: National Heart, Lung, and Blood Institute (NHLBI) Information provided by (Responsible Party): University of North Carolina, Chapel Hill Study Details Study Description Go to Brief Summary: Purpose: To determine if inhaled hypertonic saline (HS) accelerates airway mucociliary clearance (MCC) in well-controlled moderate to severe asthmatics. Condition or disease Intervention/treatment Phase Moderate to Severe Asthma Device: Hypertonic (...) Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics Phase I Assessment of Hypertonic Saline in Moderate to Severe Asthmatics - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Phase I

2018 Clinical Trials

84. Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis Full Text available with Trip Pro

the identification period. A Generalized Linear Model (GLM) with gamma distribution and log link was used to analyze costs adjusting for patient demographics.A total of 20,410 patients were included: 69.5% had mild intermittent, 18.0% mild persistent, 6.9% moderate persistent and 5.5% severe persistent asthma; with mean costs (SD) of $67 (134), $482 (1506), $1061 (1983), $2235 (3426) respectively (p < 0.001). The mean total direct cost was estimated at $331 (1278) per patient. Medication and hospitalization had (...) Health care costs and resource utilization for different asthma severity stages in Colombia: a claims data analysis Asthma is one of the most common chronic respiratory conditions worldwide. Asthma-related economic burden has been reported in Latin America, but knowledge about its economic impact to the Colombian health care system and the influence of disease severity is lacking. This study estimated direct medical costs and health care resource utilization (HCRU) in patients with asthma

2018 The World Allergy Organization journal

85. Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study Full Text available with Trip Pro

Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study Data on the prevalence of perennial versus seasonal allergic asthma in Italy are lacking; moreover, there is limited evidence on the effect of omalizumab on patient-reported outcomes in Italian patients with severe allergic asthma. PROXIMA, an observational, multicenter study, was designed to assess the prevalence of perennial versus seasonal allergic asthma (...) (cross-sectional phase) and the effect of omalizumab on improving illness perception, quality of life (QoL) and asthma control of Italian patients with severe allergic asthma (longitudinal phase).The study included a cross-sectional phase (n = 357) and a longitudinal phase (n = 123): during the longitudinal phase, patients received omalizumab (75-600 mg subcutaneously every month) and were followed-up for 12 months. The primary parameter of cross-sectional phase was prevalence of perennial allergic

2018 The World Allergy Organization journal

86. Remodeling and inflammation in preschoolers with severe recurrent wheeze and asthma outcome at school age. Full Text available with Trip Pro

(73.5%) were assessed at 10.9 years. Twenty-six (72.2%) had persistent asthma. Submucosal eosinophil counts were higher in children with severe exacerbations at school age than in those without (16/0.1 mm2 [11.2-30.4] vs 8/0.1 mm2 [2.4-17.6], P = .02), and correlated with the number of severe exacerbations (P = .04, r = .35). Submucosal neutrophil counts correlated with FEV1/FVC (P < .01, r = .47) and FEF25-75% predicted (P = .02, r = .43). Airway smooth muscle (ASM) area correlated with FEV1/FVC (P (...) Remodeling and inflammation in preschoolers with severe recurrent wheeze and asthma outcome at school age. The influence of airway remodelling and inflammation in preschoolers with severe recurrent wheeze on asthma outcomes is poorly understood.To assess their association with asthma symptoms and lung function at school age.Preschoolers (38.4 months) initially investigated with bronchial biopsies were re-assessed for asthma symptoms and lung function at school age.Thirty-six of 49 preschoolers

2018 Clinical and Experimental Allergy

87. Masitinib in the Treatment of Patients With Severe Uncontrolled Asthma and Elevated Eosinophil Levels

: February 8, 2019 Sponsor: AB Science Information provided by (Responsible Party): AB Science Study Details Study Description Go to Brief Summary: The purpose of this study is to assess the safety and efficacy of masitinib (6 mg/kg/day) in severe persistent asthma, uncontrolled with high dose of inhaled corticosteroid and with elevated eosinophil levels. Condition or disease Intervention/treatment Phase Asthma Drug: Masitinib Drug: Placebo Phase 3 Detailed Description: Masitinib is a selective tyrosine (...) .: No Keywords provided by AB Science: Severe persistent asthma Eosinophil Tyrosine kinase inhibitor Additional relevant MeSH terms: Layout table for MeSH terms Asthma Bronchial Diseases Respiratory Tract Diseases Lung Diseases, Obstructive Lung Diseases Respiratory Hypersensitivity Hypersensitivity, Immediate Hypersensitivity Immune System Diseases

2018 Clinical Trials

88. Exposure to secondhand smoke and asthma severity among children in Connecticut. Full Text available with Trip Pro

logistic regression models, adjusted for enrollment date, sex, age, race/ethnicity, area of residence, insurance type, family history of asthma, eczema, and exposure to dogs, cats, gas stove, rodents and cockroaches were used to examine the association between self-reported exposure to SHS and clinician-determined asthma severity (mild, moderate, and severe persistent vs. intermittent asthma).Of the 30,163 children with asthma enrolled in Easy Breathing, between 6 months and 18 years old, living in 161 (...) different towns in CT, exposure to SHS was associated with greater asthma severity (adjusted relative risk ratio (aRRR): 1.07 [1.00, 1.15] and aRRR: 1.11 [1.02, 1.22] for mild and moderate persistent asthma, respectively). The odds of Black and Puerto Rican/Hispanic children with asthma being exposed to SHS were twice that of Caucasian children. Though the odds of SHS exposure for publicly insured children with asthma were three times greater than the odds for privately insured children (OR: 3.02

2017 PLoS ONE

89. Further Studies of Unsuspected Emphysema in Non-Smoking Asthmatics with Persistent Expiratory Airflow Obstruction. (Abstract)

Further Studies of Unsuspected Emphysema in Non-Smoking Asthmatics with Persistent Expiratory Airflow Obstruction. Previously, we and other investigators have described reversible loss of lung elastic recoil in patients with acute and persistent, moderate-to-severe, chronic, treated asthma who never smoked, and its adverse effect on maximal expiratory airflow. In four consecutive autopsies, we reported the pathophysiologic mechanism(s) has been unsuspected mild, diffuse, middle and upper lobe (...) centrilobular emphysema.We performed prospective studies (5 to 22 years) in 25 patients (12 female) with chronic asthma, age 55 ± 15 years, who never smoked, with persistent moderate-to-severe expiratory obstruction. Studies included measuring blood eosinophils, IgE, total exhaled nitric oxide (NO), central airway NO flux, peripheral airway/alveolar NO concentration, impulse oscillometry, heliox curves, lung elastic recoil, and high-resolution thin-section (1 mm) lung CT imaging at full inspiration

2017 Chest

90. Correlation of induced sputum eosinophil levels with clinical parameters in mild and moderate persistent asthma in children aged 7-18 years. (Abstract)

Correlation of induced sputum eosinophil levels with clinical parameters in mild and moderate persistent asthma in children aged 7-18 years. Treatment decisions in asthma are currently based on clinical assessment and spirometry. Sputum eosinophil, being a marker of airway inflammation, can serve as a tool for assessing severity and response to treatment in asthma patients.To measure eosinophil percentage in induced sputum in children with asthma and correlate it with clinical asthma (...) parameters.A prospective observational study was performed at tertiary care hospital on 91 children aged 7-18 years with newly diagnosed mild or moderate persistent asthma. Theinduced sputum eosinophil percentage was obtained at the time of enrollment and three months after treatment with inhaled budesonide. Patients were specifically evaluated for five clinical parameters of asthma, i.e., days of acute exacerbations, use of salbutamol as rescue medication, emergency visits, nighttime cough and days

2017 Journal of Asthma

91. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study Full Text available with Trip Pro

Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study Omalizumab is marketed for chronic severe asthma patients who are allergic to perennial allergens. Our purpose was to investigate whether omalizumab is also effective in persistent severe asthma due to seasonal allergens. Thirty patients with oral corticosteroid-dependent asthma were treated with Omalizumab according to the dosing table (...) prednisolone consumption but no differences were detected in the intergroup comparison. Omalizumab offered the same clinical benefits in the two cohorts regardless of whether the asthma was caused by a seasonal or a perennial allergen. These results strongly suggest that allergens are the trigger in chronic asthma but that it is the persistent exposure to IgE that causes the chronicity.

2017 International journal of molecular sciences

92. Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma

Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (...) (100). Please remove one or more studies before adding more. Efficacy and Safety of PT001 to Placebo and Open-label Spiriva® Respimat® in Subjects With Persistant Asthma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier

2017 Clinical Trials

93. A Study to Assess Jia Wei Yang He Formula as a Plus Therapy in the Treatment of Persistent Asthma

A Study to Assess Jia Wei Yang He Formula as a Plus Therapy in the Treatment of Persistent Asthma A Study to Assess Jia Wei Yang He Formula as a Plus Therapy in the Treatment of Persistent Asthma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove (...) one or more studies before adding more. A Study to Assess Jia Wei Yang He Formula as a Plus Therapy in the Treatment of Persistent Asthma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03299322 Recruitment Status

2017 Clinical Trials

94. Clinical Study on Treatment of Chronic Persistent Bronchial Asthma

Clinical Study on Treatment of Chronic Persistent Bronchial Asthma Clinical Study on Treatment of Chronic Persistent Bronchial Asthma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Clinical Study (...) on Treatment of Chronic Persistent Bronchial Asthma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03228134 Recruitment Status : Not yet recruiting First Posted : July 24, 2017 Last Update Posted : December 20, 2017 See Sponsor

2017 Clinical Trials

95. Persistent asthma phenotype related with late-onset, high atopy, and low socioeconomic status in school-aged Korean children. Full Text available with Trip Pro

Persistent asthma phenotype related with late-onset, high atopy, and low socioeconomic status in school-aged Korean children. Treatment guidelines for asthma have been established based on asthma severity; there are limitations in the identification of underlying pathophysiology and prediction of prognosis in heterogeneous phenotypes of asthma. Although the complex interactions between environmental and genetic factors affect the development and progression of asthma, studies on asthma (...) , and low socioeconomic status are associated with troublesome persistent asthma phenotype in school-age children. Environmental factors might be implicated in the clinical heterogeneity of asthma. Asthma phenotypes considering diverse factors might be more helpful in the identification of asthma pathogenesis and its prevention.

2017 BMC pulmonary medicine

96. Predictors of emergency department use in children with persistent asthma in metropolitan Atlanta, Georgia. Full Text available with Trip Pro

Predictors of emergency department use in children with persistent asthma in metropolitan Atlanta, Georgia. Racial disparities are evident among children with asthma in the United States, with non-Hispanic black children at particularly high risk for poor asthma outcomes, including frequent emergency department (ED) use for asthma exacerbations.To compare asthma features in non-Hispanic black vs white children in Atlanta, Georgia, and determine what clinical features predict future ED use (...) for asthma.Self-reported black and white children 6 to 17 years of age with persistent asthma treated with controller medications completed medical history questionnaires, lung function testing, aeroallergen sensitization testing, and venipuncture. Medical records were reviewed for asthma-related ED visits for 12 months after the initial study visit.A total of 276 children were enrolled. Black children, compared with white children, resided in more disadvantaged zip code areas and were more likely to have

2017 Asthma & Immunology

97. Clinical predictors of remission and persistence of adult-onset asthma. Full Text available with Trip Pro

(15.9%) experienced asthma remission. Patients with asthma persistence were older, had worse asthma control, required higher doses of inhaled corticosteroids, had more severe airway hyperresponsiveness, more often nasal polyps, and higher levels of blood neutrophils as compared to patients who experienced clinical remission. In a multivariable logistic regression analysis, only moderate to severe bronchial hyperresponsiveness and nasal polyps were independent predictors of asthma persistence (...) Clinical predictors of remission and persistence of adult-onset asthma. Adult-onset asthma is an important but relatively understudied asthma phenotype and little is known about its natural course and prognosis. The remission rate is believed to be low, and it is still obscure which factors predict remission or persistence of the disease.This study sought to determine the remission rate and identify predictors of persistence and remission of adult-onset asthma.Two hundred adult patients

2017 Journal of Allergy and Clinical Immunology

98. Effectiveness of vitamin D3 in severe persistent asthmatic patients: A double blind, randomized, clinical study. Full Text available with Trip Pro

Effectiveness of vitamin D3 in severe persistent asthmatic patients: A double blind, randomized, clinical study. To assess the pulmonary function and quality of life in asthma patients receiving vitamin D3 supplementation with inhaled budesonide and formoterol.This was a double blinded, randomized, comparative study. Patients were recruited as per the study criteria and randomized into two groups: usual care group (n = 69) patients received budesonide (800 μg) with formoterol (24 μg (...) showed statistically significant (P < 0.05) improvement in symptom, impact and total scores.On the basis of our findings, we conclude that supplementation of vitamin D3 is effective in improving the quality of life rather than pulmonary function in severe asthmatics. However, further studies are warranted to substantiate the present findings.

2015 Journal of pharmacology & pharmacotherapeutics Controlled trial quality: uncertain

99. Efficacy and Safety of BI 655066 in Patients With Severe Persistent Asthma.

Efficacy and Safety of BI 655066 in Patients With Severe Persistent Asthma. Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies (...) before adding more. Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT02443298 Recruitment Status : Completed First Posted : May 13, 2015 Last Update Posted : September 13, 2018 Sponsor: AbbVie

2015 Clinical Trials

100. Cost-effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma. Full Text available with Trip Pro

Cost-effectiveness of bronchial thermoplasty in commercially-insured patients with poorly controlled, severe, persistent asthma. We examined the cost-effectiveness of treating poorly controlled, severe, persistent asthma patients with bronchial thermoplasty (BT), a novel technology that uses thermal energy to reduce airway smooth muscle mass, with 5-year outcome data demonstrating a durable reduction in asthma exacerbations.We conducted a model-based cost-effectiveness analysis assessing 5-year (...) healthcare utilization, patient quality of life and adverse events.We utilized Markov modeling to estimate the costs and quality-of-life impact of BT compared with high-dose combination therapy among poorly controlled, severe, persistent asthma patients: those requiring high-dose combination therapy and having experienced an asthma exacerbation-related ER visit in the past year.The cost-effectiveness of BT was US$5495 per quality-adjusted life year; and approximately 22% of sensitivity analysis

2015 Expert review of pharmacoeconomics & outcomes research

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>